Erratum: lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma (Oncology Letters (2021) 21 (455) DOI: 10.3892/ol.2021.12716)

HIDEHARU YAMADA; MASANOBU TAKAHASHI; Munenori Watanuki; Mika Watanabe; SAKURA HIRAIDE; KEN SAIJO; KEIGO KOMINE; CHIKASHI ISHIOKA

doi:10.3892/ol.2021.12959

Erratum: lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma (Oncology Letters (2021) 21 (455) DOI: 10.3892/ol.2021.12716)

HIDEHARU YAMADA, MASANOBU TAKAHASHI, Munenori Watanuki, Mika Watanabe, SAKURA HIRAIDE, KEN SAIJO, KEIGO KOMINE, CHIKASHI ISHIOKA

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Subsequently to the publication of the above paper, the authors realized that the layouts of Tables I and III had been presented incorrectly, and that they had overlooking acknowledging researchers who had provided them with the cell lines in the Acknowledgements section of the paper. Consequently, the correctly organized versions of Tables I and 3 are shown on the subsequent pages. Concerning the oversight with the Acknowledgements section, this section of the declarations should be changed to the following (added text is highlighted in bold):. (Table Presented).

Original language	English
Article number	698
Journal	Oncology Letters
Volume	22
Issue number	4
DOIs	https://doi.org/10.3892/ol.2021.12959
Publication status	Published - 2021 Oct

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3892/ol.2021.12959

Cite this

YAMADA, HIDEHARU., TAKAHASHI, MASANOBU., Watanuki, M., Watanabe, M., HIRAIDE, SAKURA., SAIJO, KEN., KOMINE, KEIGO., & ISHIOKA, CHIKASHI. (2021). Erratum: lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma (Oncology Letters (2021) 21 (455) DOI: 10.3892/ol.2021.12716). Oncology Letters, 22(4), [698]. https://doi.org/10.3892/ol.2021.12959

YAMADA, HIDEHARU, TAKAHASHI, MASANOBU, Watanuki, M, Watanabe, M, HIRAIDE, SAKURA, SAIJO, KEN , KOMINE, KEIGO & ISHIOKA, CHIKASHI 2021, 'Erratum: lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma (Oncology Letters (2021) 21 (455) DOI: 10.3892/ol.2021.12716)', Oncology Letters, vol. 22, no. 4, 698. https://doi.org/10.3892/ol.2021.12959

@article{cf54487514714dd2b7ec62ed66b4996c,

title = "Erratum: lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma (Oncology Letters (2021) 21 (455) DOI: 10.3892/ol.2021.12716)",

abstract = "Subsequently to the publication of the above paper, the authors realized that the layouts of Tables I and III had been presented incorrectly, and that they had overlooking acknowledging researchers who had provided them with the cell lines in the Acknowledgements section of the paper. Consequently, the correctly organized versions of Tables I and 3 are shown on the subsequent pages. Concerning the oversight with the Acknowledgements section, this section of the declarations should be changed to the following (added text is highlighted in bold):. (Table Presented).",

author = "HIDEHARU YAMADA and MASANOBU TAKAHASHI and Munenori Watanuki and Mika Watanabe and SAKURA HIRAIDE and KEN SAIJO and KEIGO KOMINE and CHIKASHI ISHIOKA",

year = "2021",

month = oct,

doi = "10.3892/ol.2021.12959",

language = "English",

volume = "22",

journal = "Oncology Letters",

issn = "1792-1074",

publisher = "Spandidos Publications",

number = "4",

}

TY - JOUR

T1 - Erratum

T2 - lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma (Oncology Letters (2021) 21 (455) DOI: 10.3892/ol.2021.12716)

AU - YAMADA, HIDEHARU

AU - TAKAHASHI, MASANOBU

AU - Watanuki, Munenori

AU - Watanabe, Mika

AU - HIRAIDE, SAKURA

AU - SAIJO, KEN

AU - KOMINE, KEIGO

AU - ISHIOKA, CHIKASHI

PY - 2021/10

Y1 - 2021/10

N2 - Subsequently to the publication of the above paper, the authors realized that the layouts of Tables I and III had been presented incorrectly, and that they had overlooking acknowledging researchers who had provided them with the cell lines in the Acknowledgements section of the paper. Consequently, the correctly organized versions of Tables I and 3 are shown on the subsequent pages. Concerning the oversight with the Acknowledgements section, this section of the declarations should be changed to the following (added text is highlighted in bold):. (Table Presented).

AB - Subsequently to the publication of the above paper, the authors realized that the layouts of Tables I and III had been presented incorrectly, and that they had overlooking acknowledging researchers who had provided them with the cell lines in the Acknowledgements section of the paper. Consequently, the correctly organized versions of Tables I and 3 are shown on the subsequent pages. Concerning the oversight with the Acknowledgements section, this section of the declarations should be changed to the following (added text is highlighted in bold):. (Table Presented).

UR - http://www.scopus.com/inward/record.url?scp=85112182879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112182879&partnerID=8YFLogxK

U2 - 10.3892/ol.2021.12959

DO - 10.3892/ol.2021.12959

M3 - Comment/debate

AN - SCOPUS:85112182879

VL - 22

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 4

M1 - 698

ER -

Erratum: lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma (Oncology Letters (2021) 21 (455) DOI: 10.3892/ol.2021.12716)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this